1. Chondroitin Sulphate and Glucosamine Use Depend on Nonsteroidal Anti-inflammatory Drug Use to Modify the Risk for Colorectal Cancer
- Author
-
Rosa Morros, Maria Angeles Quijada-Manuitt, Luisa C de la Peña-Negro, Elisabet Guinó, Gemma Ibáñez-Sanz, and Victor Moreno
- Subjects
Adult ,Male ,0301 basic medicine ,Drug ,medicine.medical_specialty ,Adolescent ,Epidemiology ,medicine.drug_class ,Colorectal cancer ,media_common.quotation_subject ,Population ,Gastroenterology ,Anti-inflammatory ,Young Adult ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Chondroitin sulphate ,Risk Factors ,Glucosamine ,Internal medicine ,Antineoplastic Combined Chemotherapy Protocols ,Prevalence ,Humans ,Medicine ,education ,Aged ,media_common ,Aged, 80 and over ,education.field_of_study ,Nonsteroidal ,business.industry ,Cumulative dose ,Anti-Inflammatory Agents, Non-Steroidal ,Chondroitin Sulfates ,Middle Aged ,medicine.disease ,digestive system diseases ,030104 developmental biology ,Oncology ,chemistry ,Case-Control Studies ,030220 oncology & carcinogenesis ,Female ,Colorectal Neoplasms ,business - Abstract
Background: A safe and effective colorectal cancer chemoprevention agent remains to be discovered. There is little evidence regarding the protective effect of chondroitin sulphate and glucosamine on colorectal cancer. We aimed to assess the association between colorectal cancer risk and the use of chondroitin sulphate and glucosamine using a large cohort with dispensed data. Methods: We performed a population-based case–control study in Catalonia using primary care reimbursed medication records (SIDIAP database). The study included 25,811 cases with an incident diagnosis of colorectal cancer and 129,117 matched controls between 2010 and 2015. Results: The prevalence of ever use was 9.0% (n = 13,878) for chondroitin sulphate, 7.3% (n = 11,374) for glucosamine, and 35% for regular use of nonsteroidal anti-inflammatory drugs (NSAID; n = 45,774). A decreased risk of colorectal cancer was observed among chondroitin sulphate use [OR: 0.96; 95% confidence interval (CI), 0.91–1.01], glucosamine use (OR: 0.92; 95% CI, 0.87–0.97), and concurrent use of chondroitin sulphate and glucosamine (OR: 0.83; 95% CI, 0.70–0.98). Especially for glucosamine, there was a dose–response association regarding duration and cumulative dose. The analysis stratified by simultaneous use with other NSAIDs showed that these drugs used without other NSAIDs do not reduce risk (OR: 1.06; 95% CI, 0.74–1.51). However, they may have a synergistic protective effect when used with other NSAIDs (OR: 0.80; 95% CI, 0.72–0.88). Conclusions: This study does not provide strong support for an independent protective association of chondroitin sulphate or glucosamine on colorectal cancer risk in our population. However, these drugs may have a synergistic beneficial effect among NSAID users. Impact: Chondroitin sulphate or glucosamine may contribute to the protective effect of NSAID use in colorectal cancer.
- Published
- 2020